Literature DB >> 20460893

Mouse models for experimental autoimmune hepatitis: limits and chances.

Matthias Hardtke-Wolenski1, Elmar Jaeckel.   

Abstract

The difficulty in studying human autoimmune hepatitis (AIH) is usually the late time-point of diagnosis which is followed by long-standing immunosuppression and the fact that human immune responses can usually only be studied in peripheral blood. Therefore, animal models with defined onset of AIH and, ideally, a positive impact of standard therapeutic interventions are key to understanding the disease and its pathophysiology, and providing a platform for new therapy options or better prevention. For over a century, the lack of a reliable model with a chronic immune response against hepatocytes has been a key problem in AIH research. Initial attempts to break tolerance against liver tissue resulted in mild and transient hepatitis. Many transgenic models demonstrated different aspects of liver-specific immune regulation. The fate of liver-specific T cells is under intense research and many mechanisms have demonstrated ignorance, anergy, deletion or TCR downregulation. Furthermore, these studies defined a role of professional antigen-presenting cells and especially of liver sinusoidal cells. Other models have shown the mechanism of T cell activation in liver and the interaction of adaptive and innate immune cells. Most recently, some approaches have been made to establish models of chronic AIH resembling human disease. These attempts might open new research chances to study AIH onset and its pathophysiology, and they might result in new options for therapy and prevention research. Copyright 2010 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2010        PMID: 20460893     DOI: 10.1159/000282067

Source DB:  PubMed          Journal:  Dig Dis        ISSN: 0257-2753            Impact factor:   2.404


  8 in total

Review 1.  Hepatitis mouse models: from acute-to-chronic autoimmune hepatitis.

Authors:  Muhammed Yüksel; Debby Laukens; Femke Heindryckx; Hans Van Vlierberghe; Anja Geerts; F Susan Wong; Li Wen; Isabelle Colle
Journal:  Int J Exp Pathol       Date:  2014-08-12       Impact factor: 1.925

Review 2.  Regulation of hepatocyte fate by interferon-γ.

Authors:  Christopher J Horras; Cheri L Lamb; Kristen A Mitchell
Journal:  Cytokine Growth Factor Rev       Date:  2011-02-18       Impact factor: 7.638

3.  Medullary thymic epithelial cell depletion leads to autoimmune hepatitis.

Authors:  Anthony J Bonito; Costica Aloman; M Isabel Fiel; Nichole M Danzl; Sungwon Cha; Erica G Weinstein; Seihwan Jeong; Yongwon Choi; Matthew C Walsh; Konstantina Alexandropoulos
Journal:  J Clin Invest       Date:  2013-07-15       Impact factor: 14.808

Review 4.  Natural killer T (NKT) cells in autoimmune hepatitis.

Authors:  Jochen Mattner
Journal:  Curr Opin Immunol       Date:  2013-10-19       Impact factor: 7.486

5.  Mouse liver-specific CD8(+) T-cells encounter their cognate antigen and acquire capacity to destroy target hepatocytes.

Authors:  Sylvie Chabot; Amin Fakhfakh; Kathie Béland; Alain Lamarre; Michael B A Oldstone; Fernando Alvarez; Idriss Djilali-Saiah
Journal:  J Autoimmun       Date:  2012-11-05       Impact factor: 7.094

Review 6.  Medullary thymic epithelial cells and central tolerance in autoimmune hepatitis development: novel perspective from a new mouse model.

Authors:  Konstantina Alexandropoulos; Anthony J Bonito; Erica G Weinstein; Olivier Herbin
Journal:  Int J Mol Sci       Date:  2015-01-16       Impact factor: 5.923

7.  Methylprednisolone Decreases Mitochondria-Mediated Apoptosis and Autophagy Dysfunction in Hepatocytes of Experimental Autoimmune Hepatitis Model via the Akt/mTOR Signaling.

Authors:  Xiaoli Fan; Ruoting Men; Haoran Wang; Mengyi Shen; Tingting Wang; Tinghong Ye; Xuefeng Luo; Li Yang
Journal:  Front Pharmacol       Date:  2019-10-18       Impact factor: 5.810

8.  Autoimmune hepatitis-like disease in C57BL/6 mice infected with mouse hepatitis virus A59.

Authors:  José L Aparicio; Clara Peña; Lilia A Retegui
Journal:  Int Immunopharmacol       Date:  2011-05-31       Impact factor: 4.932

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.